Alex Hearn

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

Back pain is debilitating and limiting. It forces changes to the way people live and affects their quality of lie. Gelmetix addresses the most common cause of this critical problem through an efficient, cost effective and drug-free approach to preventing pain and restoring functionality and movement. Our patented polymer gel helps to restore the natural integrity of the disc itself. Injected directly, it rehydrates and stabilises, bringing back load-bearing properties and restoring the movement of the patient. Our polymer gel technology also has the potential to be adapted and extended for other uses. Gelmetix was founded in 2012, as a spin-off from the University of Manchester. In December 2020, Gelmetix was named “one of the most promising biotech start-ups in Europe” by EIT Health Catapult.

Nuada is a vertically integrated carbon capture company that is poised to decarbonise heavy industries through its next-generation point-source capture technology. We have combined advanced solid adsorbents (Metal Organic Frameworks or MOFs) with proven vacuum swing technology to vacuum CO2 out of industrial emissions through a “heatless” and solvent-free process. The use of pressure instead of heat represents a step-change innovation that slashes the energy and costs barriers for mass adoption of carbon capture in industry. Nuada builds energy-efficient CO2 filtration machines that enable industrial emitters in hard-to-abate sectors to achieve their Net Zero targets whilst minimising the impact on their bottom line.

Small Pharma is a biotech company taking a radically different approach to mental health treatment. We believe everyone deserves the option of better mental health. We are developing a pipeline of short-duration, psychedelic-assisted treatments for under-served mental health conditions, starting with the most advanced clinical trial in commercial development for DMT-assisted psychotherapy to treat Major Depressive Disorder.

Maropost offers a unified commerce platform that empowers ecommerce merchants and retailers to scale faster, operate more efficiently, and deliver exceptional customer experiences. By bringing ecommerce, merchandising, retail, marketing automation, customer service, and AI-powered analytics into one connected ecosystem, we help brands eliminate silos, reduce operational complexity, and accelerate revenue growth. Since its founding in 2011, Maropost has supported ecommerce and retail businesses across North America, Australia, and Europe. Trusted by over 5,000 global brands – including Luxottica, Mercedes-Benz, Seiko, Intersport, and Fujifilm – Maropost has earned recognition on Deloitte’s Technology Fast 500 and G2’s industry leaderboards. Maropost operates as a hybrid company, with team members working remotely, in office, or through a mix of both. We’re headquartered in Toronto, Canada, with additional offices in Mohali (India), Brisbane and the Sunshine Coast (Australia), and Stockholm (Sweden). To learn more about Maropost, visit www.maropost.com.

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

Back pain is debilitating and limiting. It forces changes to the way people live and affects their quality of lie. Gelmetix addresses the most common cause of this critical problem through an efficient, cost effective and drug-free approach to preventing pain and restoring functionality and movement. Our patented polymer gel helps to restore the natural integrity of the disc itself. Injected directly, it rehydrates and stabilises, bringing back load-bearing properties and restoring the movement of the patient. Our polymer gel technology also has the potential to be adapted and extended for other uses. Gelmetix was founded in 2012, as a spin-off from the University of Manchester. In December 2020, Gelmetix was named “one of the most promising biotech start-ups in Europe” by EIT Health Catapult.

Nuada is a vertically integrated carbon capture company that is poised to decarbonise heavy industries through its next-generation point-source capture technology. We have combined advanced solid adsorbents (Metal Organic Frameworks or MOFs) with proven vacuum swing technology to vacuum CO2 out of industrial emissions through a “heatless” and solvent-free process. The use of pressure instead of heat represents a step-change innovation that slashes the energy and costs barriers for mass adoption of carbon capture in industry. Nuada builds energy-efficient CO2 filtration machines that enable industrial emitters in hard-to-abate sectors to achieve their Net Zero targets whilst minimising the impact on their bottom line.

Small Pharma is a biotech company taking a radically different approach to mental health treatment. We believe everyone deserves the option of better mental health. We are developing a pipeline of short-duration, psychedelic-assisted treatments for under-served mental health conditions, starting with the most advanced clinical trial in commercial development for DMT-assisted psychotherapy to treat Major Depressive Disorder.